Taiwan FDA granted the API Market License of Bortezomib "GBC"
Taiwan FDA granted the in-house developed Generic Oncology (Cytotoxic) Active Pharmaceutical Ingredient Market License of Bortezomib, Registration Number: MOHW-PM060602 (DMF No. : DMF(00)3578)
